Imprimis Pharmaceuticals Inc(NASDAQ:IMMY) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-Market on Mar 21, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Earnings per share were $-0.3.
Imprimis Pharmaceuticals Inc (IMMY) made into the market gainers list on Fridays trading session with the shares advancing 10.16% or 0.26 points. Due to strong positive momentum, the stock ended at $2.82, which is also near the day’s high of $2.8782. The stock began the session at $2.54 and the volume stood at 1,94,570 shares. The 52-week high of the shares is $4.467 and the 52 week low is $1.65. The company has a current market capitalization of $53 M and it has 1,86,27,915 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Dec 21, 2016, Richard L Md Lindstrom (director) purchased 100,000 shares at $1.79 per share price.Also, On Dec 21, 2016, Andrew R. Boll (CFO) purchased 39,000 shares at $1.79 per share price.On Dec 21, 2016, Mark L Baum (CEO) purchased 156,000 shares at $1.79 per share price, according to the Form-4 filing with the securities and exchange commission.
Imprimis Pharmaceuticals Inc. (Imprimis) is a pharmaceutical company. The Company focuses on developing and commercializing compounded drug therapies and making these therapies available to physicians and patients. It owns markets and sells a portfolio of combination formulations in ophthalmology and urology. Its ophthalmology formulation portfolio includes Dropless Therapy and LessDrops formulations which serve the eye drop market. Its Defeat IC campaign includes a compounded formulation for patients suffering from interstitial cystitis. It makes dispenses and sells its compounded formulations as well as other non-proprietary products through its compounding pharmacies Pharmacy Creations LLC (Pharmacy Creations) and Park. Its pharmacies also dispense prescriptions for complementary compounded formulations within the ophthalmology and urology therapeutic areas as well as other compounded formulations in other therapeutic areas for an individually identified patient.